Design and synthesis of lactam–thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors
摘要:
Herein we report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors. Optimizing potency in a replicon assay and minimizing potential risk for CYP3A4 induction led to the discovery of inhibitor 22a. This lead compound has a favorable pharmacokinetic profile in rats and dogs. (C) 2014 Elsevier Ltd. All rights reserved.
Design and synthesis of lactam–thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors
摘要:
Herein we report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors. Optimizing potency in a replicon assay and minimizing potential risk for CYP3A4 induction led to the discovery of inhibitor 22a. This lead compound has a favorable pharmacokinetic profile in rats and dogs. (C) 2014 Elsevier Ltd. All rights reserved.
Le Guillanton,G., Bulletin de la Societe Chimique de France, 1969, p. 2871 - 2875
作者:Le Guillanton,G.
DOI:——
日期:——
Design and synthesis of lactam–thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors
作者:David Barnes-Seeman、Carri Boiselle、Christina Capacci-Daniel、Rajiv Chopra、Keith Hoffmaster、Christopher T. Jones、Mitsunori Kato、Kai Lin、Sue Ma、Guoyu Pan、Lei Shu、Jianling Wang、Leah Whiteman、Mei Xu、Rui Zheng、Jiping Fu
DOI:10.1016/j.bmcl.2014.06.031
日期:2014.8
Herein we report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors. Optimizing potency in a replicon assay and minimizing potential risk for CYP3A4 induction led to the discovery of inhibitor 22a. This lead compound has a favorable pharmacokinetic profile in rats and dogs. (C) 2014 Elsevier Ltd. All rights reserved.